Wells Fargo’s Rallybio RLYB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-74
Closed -$592 – 7550
2026
Q2
$592 Hold
74
– – ﹤0.01% 6505
2026
Q1
$332 Sell
74
-1
-1% -$3 ﹤0.01% 6428
2025
Q4
$206 Hold
75
– – ﹤0.01% 6391
2025
Q3
$150 Sell
75
-9,933
-99% -$20.9K ﹤0.01% 6360
2025
Q2
$13.5K Sell
10,008
-542
-5% -$718 ﹤0.01% 5874
2025
Q1
$27.6K Buy
10,550
+475
+5% +$1.5K ﹤0.01% 5603
2024
Q4
$38.7K Sell
10,075
-2,500
-20% -$10.5K ﹤0.01% 5568
2024
Q3
$58.9K Buy
12,575
+3,125
+33% +$15.1K ﹤0.01% 5286
2024
Q2
$50.7K Buy
9,450
+2,946
+45% +$20K ﹤0.01% 5286
2024
Q1
$48.1K Buy
6,504
+4,097
+170% +$28.5K ﹤0.01% 5267
2023
Q4
$23K Buy
2,407
+463
+24% +$5.66K ﹤0.01% 5598
2023
Q3
$26.2K Sell
1,944
-1,023
-34% -$22.2K ﹤0.01% 5487
2023
Q2
$67.2K Buy
2,967
+1,997
+206% +$48.9K ﹤0.01% 5268
2023
Q1
$22.1K Buy
970
+895
+1,193% +$23.1K ﹤0.01% 5593
2022
Q4
$1.97K Sell
75
-56
-43% -$1.65K ﹤0.01% 6015
2022
Q3
$7K Sell
131
-27
-17% -$1.2K ﹤0.01% 5822
2022
Q2
$5K Sell
158
-759
-83% -$28.5K ﹤0.01% 6023
2022
Q1
$26K Sell
917
-57
-6% -$2.36K ﹤0.01% 5929
2021
Q4
$37K Buy
974
+964
+9,640% +$56.1K ﹤0.01% 6107
2021
Q3
$1K Buy
+10
New +$586 ﹤0.01% 6779

Other funds holding RLYB

Wells Fargo's RLYB Position: Q3 2026 in Review

Wells Fargo sold out of Rallybio (RLYB) in Q3 2026, closing a stake of 74 shares — an estimated $592 sold.

Wells Fargo first reported a position in RLYB in Q3 2021 and held it in 20 quarters. The position peaked at $67.2K in Q2 2023. 32 funds tracked by Wall St. Rank hold RLYB as of Q3 2026.

  • Wells Fargo reported no remaining Rallybio position as of Q3 2026 after selling out during the quarter.
  • Wells Fargo sold 74 Rallybio shares in Q3 2026, an estimated $592.
  • Wells Fargo first reported a position in Rallybio in Q3 2021 and held it in 20 quarters.
  • Wells Fargo's Rallybio position peaked at $67.2K in Q2 2023.
  • 32 funds tracked by Wall St. Rank held Rallybio as of Q3 2026.

Based on Wells Fargo's 13F filing for Q3 2026, filed 16 Nov 2026.